One-carbon Pathway Metabolites Are Altered in the Plasma of Subjects with Down Syndrome: Relation to Chromosomal Dosage

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Dec 19

PMID 36530924

Authors

Beatrice Vione

Giuseppe Ramacieri

Giacomo Zavaroni

Angela Piano

Giorgia La Rocca

Maria Caracausi

Lorenza Vitale

Allison Piovesan

Caterina Gori

Gian Luca Pirazzoli

Pierluigi Strippoli

Guido Cocchi

Luigi Corvaglia

Chiara Locatelli

Maria Chiara Pelleri

Francesca Antonaros

Affiliations

Soon will be listed here.

Abstract

Introduction: Down syndrome (DS) is the most common chromosomal disorder and it is caused by trisomy of chromosome 21 (Hsa21). Subjects with DS show a large heterogeneity of phenotypes and the most constant clinical features present are typical facies and intellectual disability (ID). Several studies demonstrated that trisomy 21 causes an alteration in the metabolic profile, involving among all the one-carbon cycle.

Methods: We performed enzyme-linked immunosorbent assays (ELISAs) to identify the concentration of 5 different intermediates of the one-carbon cycle in plasma samples obtained from a total of 164 subjects with DS compared to 54 euploid subjects. We investigated: tetrahydrofolate (THF; DS = 108, control = 41), 5-methyltetrahydrofolate (5-methyl-THF; DS = 140, control = 34), 5-formyltetrahydrofolate (5-formyl-THF; DS = 80, control = 21), S-adenosyl-homocysteine (SAH; DS = 94, control = 20) and S-adenosyl-methionine (SAM; DS = 24, control = 15).

Results: Results highlight specific alterations of THF with a median concentration ratio DS/control of 2:3, a decrease of a necessary molecule perfectly consistent with a chromosomal dosage effect. Moreover, SAM and SAH show a ratio DS/control of 1.82:1 and 3.6:1, respectively.

Discussion: The relevance of these results for the biology of intelligence and its impairment in trisomy 21 is discussed, leading to the final proposal of 5-methyl-THF as the best candidate for a clinical trial aimed at restoring the dysregulation of one-carbon cycle in trisomy 21, possibly improving cognitive skills of subjects with DS.

Citing Articles

Metabolomics of mothers of children with autism, idiopathic developmental delay, and Down syndrome.

Parenti M, Shoff S, Sotelo-Orozco J, Hertz-Picciotto I, Slupsky C Sci Rep. 2024; 14(1):31981.

PMID: 39738617 PMC: 11686393. DOI: 10.1038/s41598-024-83587-x.

General Dietary Recommendations for People with Down Syndrome.

Gruszka J, Wlodarek D Nutrients. 2024; 16(16).

PMID: 39203792 PMC: 11357503. DOI: 10.3390/nu16162656.

Metabolite Biomarkers of Prolonged and Intensified Pain and Distress in Head and Neck Cancer Patients Undergoing Radio- or Chemoradiotherapy by Means of NMR-Based Metabolomics-A Preliminary Study.

Boguszewicz L, Heyda A, Ciszek M, Bielen A, Skorupa A, Mrochem-Kwarciak J Metabolites. 2024; 14(1).

PMID: 38248863 PMC: 10819132. DOI: 10.3390/metabo14010060.

Down Syndrome: how to communicate the diagnosis.

Gori C, Cocchi G, Corvaglia L, Ramacieri G, Pulina F, Sperti G Ital J Pediatr. 2023; 49(1):18.

PMID: 36759877 PMC: 9912489. DOI: 10.1186/s13052-023-01419-6.

References

LeJeune J, Rethore M, de Blois M, Mir M, Nicolle L, Borowy F . [Metabolism of monocarbons and trisomy 21: sensitivity to methotrexate]. Ann Genet. 1986; 29(1):16-9. View

Zheng Y, Cantley L . Toward a better understanding of folate metabolism in health and disease. J Exp Med. 2018; 216(2):253-266. PMC: 6363433. DOI: 10.1084/jem.20181965. View

Nazki F, Sameer A, Ganaie B . Folate: metabolism, genes, polymorphisms and the associated diseases. Gene. 2013; 533(1):11-20. DOI: 10.1016/j.gene.2013.09.063. View

Pelleri M, Cicchini E, Locatelli C, Vitale L, Caracausi M, Piovesan A . Systematic reanalysis of partial trisomy 21 cases with or without Down syndrome suggests a small region on 21q22.13 as critical to the phenotype. Hum Mol Genet. 2016; 25(12):2525-2538. PMC: 5181629. DOI: 10.1093/hmg/ddw116. View

Anderson C, Marentette J, Prutton K, Rauniyar A, Reisz J, DAlessandro A . Trisomy 21 results in modest impacts on mitochondrial function and central carbon metabolism. Free Radic Biol Med. 2021; 172:201-212. PMC: 8355208. DOI: 10.1016/j.freeradbiomed.2021.06.003. View

Pecze L, Randi E, Szabo C . Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome. Mol Med. 2020; 26(1):102. PMC: 7653803. DOI: 10.1186/s10020-020-00225-8. View

Greenberg J, Bell S . Multivitamin Supplementation During Pregnancy: Emphasis on Folic Acid and l-Methylfolate. Rev Obstet Gynecol. 2012; 4(3-4):126-7. PMC: 3250974. View

Mircher C, Sacco S, Bouis C, Gallard J, Pichot A, Le Galloudec E . Thyroid hormone and folinic acid in young children with Down syndrome: the phase 3 ACTHYF trial. Genet Med. 2019; 22(1):44-52. DOI: 10.1038/s41436-019-0597-8. View

Kronenberg G, Colla M, Endres M . Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med. 2009; 9(3):315-23. DOI: 10.2174/156652409787847146. View

10.

Obeid R, Hartmuth K, Herrmann W, Gortner L, Rohrer T, Geisel J . Blood biomarkers of methylation in Down syndrome and metabolic simulations using a mathematical model. Mol Nutr Food Res. 2012; 56(10):1582-9. DOI: 10.1002/mnfr.201200162. View

11.

Antonarakis S . Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet. 2016; 18(3):147-163. DOI: 10.1038/nrg.2016.154. View

12.

Antonarakis S . Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms. Down Syndrome Collaborative Group. N Engl J Med. 1991; 324(13):872-6. DOI: 10.1056/NEJM199103283241302. View

13.

de la Torre R, de Sola S, Hernandez G, Farre M, Pujol J, Rodriguez J . Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016; 15(8):801-810. DOI: 10.1016/S1474-4422(16)30034-5. View

14.

Mentch S, Locasale J . One-carbon metabolism and epigenetics: understanding the specificity. Ann N Y Acad Sci. 2015; 1363:91-8. PMC: 4801744. DOI: 10.1111/nyas.12956. View

15.

Peeters M, Rethore M, LeJeune J . In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome. Br J Haematol. 1995; 89(3):678-80. DOI: 10.1111/j.1365-2141.1995.tb08390.x. View

16.

Antonaros F, Lanfranchi S, Locatelli C, Martelli A, Olivucci G, Cicchini E . One-carbon pathway and cognitive skills in children with Down syndrome. Sci Rep. 2021; 11(1):4225. PMC: 7895965. DOI: 10.1038/s41598-021-83379-7. View

17.

Ifergan I, Shafran A, Jansen G, Hooijberg J, Scheffer G, Assaraf Y . Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem. 2004; 279(24):25527-34. DOI: 10.1074/jbc.M401725200. View

18.

Rosenblatt D, Whitehead V, Matiaszuk N, Pottier A, Vuchich M, Beaulieu D . Differential effects of folinic acid and glycine, adenosine, and thymidine as rescue agents in methotrexate-treated human cells in relation to the accumulation of methotrexate polyglutamates. Mol Pharmacol. 1982; 21(3):718-22. View

19.

Irons M, Levy H, OFLYNN M, Stack C, Langlais P, Butler I . Folinic acid therapy in treatment of dihydropteridine reductase deficiency. J Pediatr. 1987; 110(1):61-7. DOI: 10.1016/s0022-3476(87)80289-5. View

20.

Li D, Karp N, Wu Q, Wang X, Melnyk S, James S . Mefolinate (5-methyltetrahydrofolate), but not folic acid, decreases mortality in an animal model of severe methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis. 2008; 31(3):403-11. DOI: 10.1007/s10545-008-0645-z. View